QNASL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Qnasl, and when can generic versions of Qnasl launch?
Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There is one patent protecting this drug.
This drug has forty-seven patent family members in twenty-nine countries.
The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Qnasl
A generic version of QNASL was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for QNASL?
- What are the global sales for QNASL?
- What is Average Wholesale Price for QNASL?
Summary for QNASL
| International Patents: | 47 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for QNASL |
US Patents and Regulatory Information for QNASL
QNASL is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-002 | Dec 17, 2014 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva Branded Pharm | QNASL | beclomethasone dipropionate | AEROSOL, METERED;NASAL | 202813-001 | Mar 23, 2012 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QNASL
When does loss-of-exclusivity occur for QNASL?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 11316124
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2013008824
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 14212
Estimated Expiration: ⤷ Start Trial
Chile
Patent: 13000958
Estimated Expiration: ⤷ Start Trial
China
Patent: 3282070
Estimated Expiration: ⤷ Start Trial
Patent: 6178205
Estimated Expiration: ⤷ Start Trial
Patent: 6178206
Estimated Expiration: ⤷ Start Trial
Croatia
Patent: 0150452
Estimated Expiration: ⤷ Start Trial
Patent: 0190337
Estimated Expiration: ⤷ Start Trial
Cyprus
Patent: 16292
Estimated Expiration: ⤷ Start Trial
Patent: 21719
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 27386
Estimated Expiration: ⤷ Start Trial
Patent: 26855
Estimated Expiration: ⤷ Start Trial
Eurasian Patent Organization
Patent: 3795
Estimated Expiration: ⤷ Start Trial
Patent: 1390490
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 27386
Estimated Expiration: ⤷ Start Trial
Patent: 26855
Estimated Expiration: ⤷ Start Trial
Hong Kong
Patent: 14990
Estimated Expiration: ⤷ Start Trial
Hungary
Patent: 43276
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 5712
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 23247
Estimated Expiration: ⤷ Start Trial
Patent: 50236
Estimated Expiration: ⤷ Start Trial
Patent: 13541378
Estimated Expiration: ⤷ Start Trial
Patent: 15147061
Estimated Expiration: ⤷ Start Trial
Lithuania
Patent: 26855
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 6164
Estimated Expiration: ⤷ Start Trial
Patent: 13003840
Estimated Expiration: ⤷ Start Trial
New Zealand
Patent: 8218
Estimated Expiration: ⤷ Start Trial
Peru
Patent: 131492
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 27386
Estimated Expiration: ⤷ Start Trial
Patent: 26855
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 27386
Estimated Expiration: ⤷ Start Trial
Patent: 26855
Estimated Expiration: ⤷ Start Trial
San Marino
Patent: 01500114
Estimated Expiration: ⤷ Start Trial
Patent: 01900135
Estimated Expiration: ⤷ Start Trial
Serbia
Patent: 037
Estimated Expiration: ⤷ Start Trial
Patent: 574
Estimated Expiration: ⤷ Start Trial
Singapore
Patent: 9892
Estimated Expiration: ⤷ Start Trial
Slovenia
Patent: 27386
Estimated Expiration: ⤷ Start Trial
Patent: 26855
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 1301938
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 1559639
Estimated Expiration: ⤷ Start Trial
Patent: 130100334
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 36969
Estimated Expiration: ⤷ Start Trial
Patent: 12996
Estimated Expiration: ⤷ Start Trial
Turkey
Patent: 1902415
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering QNASL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2011316124 | ⤷ Start Trial | |
| Brazil | 112013008824 | ⤷ Start Trial | |
| Canada | 2814212 | ⤷ Start Trial | |
| Chile | 2013000958 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch